Lincoln National Corp’s BlackRock Health Sciences Trust BME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-4,316
Closed -$209K 918
2021
Q4
$209K Buy
4,316
+57
+1% +$2.7K ﹤0.01% 835
2021
Q3
$203K Buy
4,259
+53
+1% +$2.58K ﹤0.01% 816
2021
Q2
$204K Buy
+4,206
New +$201K ﹤0.01% 809
2020
Q3
Sell
-5,458
Closed -$223K 686
2020
Q2
$223K Buy
+5,458
New +$220K 0.01% 573
2020
Q1
Sell
-5,296
Closed -$225K 595
2019
Q4
$225K Buy
5,296
+78
+1% +$3.09K 0.01% 578
2019
Q3
$200K Buy
5,218
+80
+2% +$3.08K 0.01% 543
2019
Q2
$200K Buy
5,138
+82
+2% +$3.12K 0.01% 528
2019
Q1
$201K Buy
+5,056
New +$200K 0.01% 484

Other funds holding BME

Lincoln National Corp's BME Position: Q1 2022 in Review

Lincoln National Corp sold out of BlackRock Health Sciences Trust (BME) in Q1 2022, closing a stake of 4,316 shares — an estimated $209K sold.

Lincoln National Corp first reported a position in BME in Q1 2019 and held it in 8 quarters. The position peaked at $225K in Q4 2019. 58 funds tracked by Wall St. Rank hold BME as of Q1 2022.

  • Lincoln National Corp reported no remaining BlackRock Health Sciences Trust position as of Q1 2022 after selling out during the quarter.
  • Lincoln National Corp sold 4,316 BlackRock Health Sciences Trust shares in Q1 2022, an estimated $209K.
  • Lincoln National Corp first reported a position in BlackRock Health Sciences Trust in Q1 2019 and held it in 8 quarters.
  • Lincoln National Corp's BlackRock Health Sciences Trust position peaked at $225K in Q4 2019.
  • 58 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust as of Q1 2022.

Based on Lincoln National Corp's 13F filing for Q1 2022, filed 9 May 2022.